Common BP lowering drugs linked to skin cancer risk: Study

Image
IANS London
Last Updated : Dec 05 2017 | 2:55 PM IST

Long term use of drugs that help lower high blood pressure may increase the risk of developing skin cancer, a study with nearly 80,000 participants has claimed.

Hydrochlorothiazide -- one of the most commonly used antihypertensive drugs worldwide -- is a thiazide diuretic (water pill) that helps prevent your body from absorbing too much salt, which can cause fluid retention.

The findings revealed that using medicines that contain hydrochlorothiazide increases the risk of developing squamous cell carcinoma -- skin cancer that develops in the cells of the outer layer of the skin -- up to seven times.

"We knew that hydrochlorothiazide made the skin more vulnerable to damage from the sun's UV rays, but what is new and also surprising is that long term use of this blood pressure medicine leads to such a significant increase in the risk of skin cancer," said Anton Pottegard, associate professor at the University of Southern Denmark.

The researchers had previously demonstrated that hydrochlorothiazide can increase the risk of lip cancer.

In the study, published in the Journal of the American Association of Dermatology, the team observed zero risk of skin cancer with other commonly used hypertension medicines.

However, one should not interrupt the treatment without consulting the doctor, Pottegard suggested, because "hydrochlorothiazide is an effective and otherwise safe treatment for most patients".

Besides treating hypertension, hydrochlorothiazide is frequently used for the treatment of congestive heart failure, symptomatic edema, diabetes insipidus and renal tubular acidosis.

The pill is also used for the prevention of kidney stones in those who have high levels of calcium in their urine.

"Nevertheless, our results should lead to a reconsideration of the use of hydrochlorothiazide. Hopefully, with this study, we can contribute towards ensuring safer treatment of high blood pressure in the future," Pottegard noted.

--IANS

rt/ksk/bg

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 05 2017 | 2:52 PM IST

Next Story